期刊文献+

中心型非小细胞肺癌三维适形放疗与调强放疗治疗计划比较 被引量:2

Comparison of treatment planning between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for central non-small cell lung cancer
原文传递
导出
摘要 目的:对比研究中心型非小细胞肺癌(NSCLC)三维适形放疗(3D-CRT)和正向调强(fIMRT)及逆向调强(iIM-RT)放疗计划特点,为中心型NSCLC放疗计划制定提供指导。方法:选择拟行根治性放疗的21例中心型NSCLC患者进行3D-CRT、fIMRT和iIMRT治疗计划设计,对3种治疗计划的相关剂量学参数进行比较。结果:3D-CRT、fIMRT和iIMRT治疗计划的适形指数(CI)差异有统计学意义,P=0.000;均匀性指数(HI)差异也有统计学意义,P=0.032。全肺V20和全肺平均受照剂量(MLD)差异均无统计学意义,P值分别为0.896和0.926;全肺V10和全肺V35组间差异均有统计学意义,P值分别为0.001和0.022;全肺V15和全肺V30组间差异为临界值,P值分别为0.058和0.051。心脏Dmean组间差异无统计学意义,P=0.989;心脏V40组间差异也无统计学意义,P=0.934。食管V45组间差异无统计学意义,P=0.708。脊髓Dmax组间差异无统计学意义,P=0.216。结论:对中心型NSCLC而言,采用iIMRT可以获得更好的靶区适形度,但iIMRT计划的剂量均匀性优势并不显著。iIMRT对中心型NSCLC正常肺组织的影响需要辨证看待,其并没有显著降低全肺V20和MLD而且增加了全肺V10、V15及键侧肺V5、V10、V15,但其显著降低了全肺V30。iIMRT没能使中心型NSCLC患者心脏、食管及脊髓受照剂量显著下降。 OBJECTIVE:To investigate the dosimetric characteristics of treatment planning of three-dimensional conformal radiotherapy,forward intensity-modulated radiotherapy, inverse intensity-modulated radiotherapy for central non-small cell lung cancer (NSCLC) to serve as guideline in clinical practice of treatment planning making for central NSCLC. METHODS.. The treatment planning of three-dimensional conformal radiotherapy (3D-CRT), forward intensity-modulated radiotherapy (fIMRT) and inverse intensity-modulated radiotherapy (iIMRT) were separately designed on the CT simulation image of the selected twenty-one patients with central NSCLC who were prescribed to receive radical radiotherapy. The advantage and disadvantage of the three different treatment planning were compared based on the dosimetric characteristics. RESULTS:The difference of CI between three groups was statistically significant (P= 0. 000), HI (P = 0. 032). The difference of V20 and MLD of the whole lungs were all not statistically significant (P value were 0. 896 and 0. 926 ,respectively), but statistically significant for V10 and V30 (P value were 0. 001 and 0. 022, respectively), statistically marginally significant for V15 and V30 (P value were 0. 058 and 0. 051). The difference of D of the heart between three groups was not statistically significant (P=0. 989) ,also V40 of the heart (P=0. 934). There was not statistically significant between the groups for V40 of the esophagus (P=0. 708) ,and for Dmax of the spinal cord (P=0. 216). CONCLUSIONS: For central NSCLC, the better conformal index (CI) of the target can be formed by iIMRT, but the advantage of heterogeneity index (HI) of iIMRT is not more marked. We need to treat the influence of iIMRT in a dialectical perspective on the normal lung tissue for the patients with NSCLC. In iIMRT planning, V20 and MLD of the whole lung is not been decreased and V10 and V15 of the whole lung and Vs, V10 and V15 of the opposite lung is also not been decreased, but V30 of the whole lung is been markedly increased. The named dosage for the heart, esophagus and spinal cord in iIMRT planning does not markedly decrease for the patients with central NSCLC.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2012年第21期1656-1660,共5页 Chinese Journal of Cancer Prevention and Treatment
基金 山东省科技发展计划(2012GSF11839) 山东省自然基金(ZR2011HM004)
关键词 非小细胞肺 放射治疗计划 计算机辅助 放射疗法 适形 carcinoma,non-small cell lung radiotherapy planning,computer-assisted radiotherapy,conformal
  • 相关文献

参考文献7

  • 1Brennan SM,Thirion P,Buckney S. Factors influencing conformity index in radiotherapy for non-small cell lung cancer[J].Medical Dosimetry,2010,(01):38-42.
  • 2Wu VW,Kwong DL,Sham JS. Target dose conformity in 3-dimensional conformal radiotherapy and intensity modulated radiotherapy[J].Radiotherapy and Oncology,2004,(02):201-206.
  • 3Katarzyna Komosi(n)ska,Marta Gi(z)y(n)ska,Anna Zawadzka. Does the IMRT technique allow improvement of treatment plans (e.g.lung sparing) for lung cancer patients with small lung volume:a planning study[J].Rep Pract Oncol Radiother,2008,(05):220-226.
  • 4邢军,李建彬,于金明,卢洁,徐敏,范廷勇,邵倩,郭守芳.非小细胞肺癌三维适形放疗剂量体积直方图参数与放射性肺损伤CT分级的关系[J].中华肿瘤杂志,2008,30(9):676-681. 被引量:5
  • 5Jin H,Tuckerc SL,Liu HH. Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy[J].Radiotherapy and Oncology,2009,(03):427-432.
  • 6Schallenkamp JM,Miller RC,Brinkmann DH. Incidence of radiation pneumonitis after thoracic irradiation:Dose-volume correlates[J].International Journal of Radiation Oncology,Biology,Physics,2007,(02):410-416.
  • 7Marks LB,Bentzen SM,Deasy JO. Radiation dose-volume effects in the lung[J].International Journal of Radiation Oncology,Biology,Physics,2010,(3 Suppl):70-76.

二级参考文献15

  • 1邢军,李建彬,于金明.影像引导非小细胞肺癌适形调强放疗技术进展[J].中华肿瘤杂志,2007,29(6):401-404. 被引量:6
  • 2Aoki T, Nagata Y, Negoro Y, et al. Evaluation of lung injury after three-dimensional conformal stereotaetic radiation therapy for solitary lung tumors : CT appearance. Radiology, 2004, 230 : 101- 108.
  • 3Park KJ, Chung JY, Chun MS, et al. Radiation-induced lung disease and the impact of radiation methods on imaging features. Radiographics, 2000, 20:83-98.
  • 4Yorke ED, Jackson A, Rosenzweig KE, et al. Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys, 2005, 63:672-682.
  • 5Rodrigues G,Lock M, D'Souza D, et al. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer: a systematic review. Radiother Oncol, 2004, 71:127-138.
  • 6Seppenwoolde Y, Lebesque JV, de Jaeger K, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys, 2003, 55:724-735.
  • 7Tyldesley S, Boyd C, Schulze K, et al. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys, 2001, 49: 973-985.
  • 8Libshitz HI, Shuman LS. Radiation-induced pulmonary change: CT findings. J Comput Assist Tomogr, 1984, 8:15-19.
  • 9Lee SW, Choi EK, Lee JS, et al. Phase Ⅱ study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and eisplatin chemotherapy for Stage Ⅲ locally advanced, unresectable, non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2003, 56:996-1004.
  • 10Oetzel D, Schraube P, Hensley F, et al. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys, 1995, 33:455- 460.

共引文献4

同被引文献17

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部